Screen2Prevent (S2P)

Part of paid clinical trials in Tampa, Florida.

Sponsor
Westat
Study ID
NCT07728123
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
14 Years - 24 Years
Healthy Volunteers
Accepted

Interventions

  • HIV screening strategies — OTHER
    The intervention includes three screening strategies (targeted, universally offered opt-in, and universally offered opt-out) which will each be employed, one at a time, for a period of 8 months. A targeted screening approach is defined as screening those who are at increased likelihood for acquiring HIV. Alternatively, a universally offered screening approach is defined as screening all, regardless of behavior informing risk. There are two types of universally offered screening, opt-in and opt-out. With opt-in screening, all patients are offered screening, which they may then agree to undergo. Opt-out screening consists of notifying patients that the test will be conducted unless they explicitly decline. Each screening strategy implements the cSHS, a text messaging platform, and Clinical Decision Support for identification of youth needing HIV treatment/prevention and linkage to services.

Study Details

Screen2Prevent is a study intended to improve HIV prevention and detection through implementation and evaluation of three different broad-scale HIV screening approaches a) targeted, b) universally offered opt-in, and c) universally offered opt-out in Emergency Departments (EDs) by leveraging digital health to identify and link adolescents seeking care in the ED to HIV Pre-Exposure Prophylaxis (PrEP)/Antiretroviral treatment (ART).

Key Dates

First listed
Jul 27, 2026
Start date
Jun 16, 2026
Status verified
Jul 2026
Primary completion
Oct 31, 2028
Completion
Oct 31, 2028

Study Design

Enrollment
84,000 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING

Arms

  • Other: 1. Universally offered opt-in > Universally offered opt-out > Targeted
    The intervention includes three screening strategies (targeted, universally offered opt-in, and universally offered opt-out) which will each be employed, one at a time, for a period of 8 months.
  • Other: 2. Universally offered opt-out > Universally offered opt-in > Targeted
    The intervention includes three screening strategies (targeted, universally offered opt-in, and universally offered opt-out) which will each be employed, one at a time, for a period of 8 months.
  • Other: 3. Universally offered opt-in > Targeted > Universally offered opt-out
    The intervention includes three screening strategies (targeted, universally offered opt-in, and universally offered opt-out) which will each be employed, one at a time, for a period of 8 months.
  • Other: 4. Universally offered opt-out > Targeted > Universally offered opt-in
    The intervention includes three screening strategies (targeted, universally offered opt-in, and universally offered opt-out) which will each be employed, one at a time, for a period of 8 months.
  • Other: 5. Targeted > Universally offered opt-out > Universally offered opt-in
    The intervention includes three screening strategies (targeted, universally offered opt-in, and universally offered opt-out) which will each be employed, one at a time, for a period of 8 months.
  • Other: 6. Targeted > Universally offered opt-in > Universally offered opt-out
    The intervention includes three screening strategies (targeted, universally offered opt-in, and universally offered opt-out) which will each be employed, one at a time, for a period of 8 months.

Primary Outcome Measure

Monthly HIV detection rates per 1,000 eligible patients [ Time Frame: 36 months ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
University of South FloridaTampaFlorida33612
Elizabeth Enriquez-Bruce
813-250-2574
Carina Rodriguez, MD (PRINCIPAL_INVESTIGATOR)
Emory Atlanta Adolescent ConsortiumAtlantaGeorgia30322
Kaylin Dance
404-727-5642
Andres Camacho-Gonzalez, MD (PRINCIPAL_INVESTIGATOR)
Johns Hopkins UniversityBaltimoreMaryland21287
Jessica Coleman-Lewis, MD
3013854868
Errol Fields, MD (PRINCIPAL_INVESTIGATOR)
St. Jude Children's Research HospitalMemphisTennessee38015
Jamie Russell
901-595-8300
Aditya Gaur, MD (PRINCIPAL_INVESTIGATOR)
Baylor College of MedicineHoustonTexas77030
Litty Koshy
832-822-1038
Mary Paul, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Tampa, FL

By condition
By specialty

Related Studies